The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
The latest contributions from J&J, Gilead, BMS, Merck & Co, Bayer, Novo Nordisk, Lilly, and Daiichi Sankyo in funding and donations supporting relief efforts against COVID-19.
J&J Commits $50 M To Support COVID Frontline Health...
Alnylam Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company focused on RNA interference (RNAi) therapeutics, and Blackstone Life Sciences, a private investment firm, have formed a collaboration under...
The latest from pharma companies on developments of potential COVID-19 treatments with news from Novartis, Amgen, Pfizer, GSK, CSL, Takeda, Biotest, Inovio Pharmaceuticals, and Hope Biosciences.
In this roundup:
Novartis Initiates Clinical...
The US Food and Drug Administration reported earlier this month (April 1, 2020) that it has requested manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs, used as anti-acids, from the market.
This is the latest step...
Mylan donates hydroxychloroquine, a potential COVID-19 treatment. Merck & Co., Pfizer, and Eli Lilly and Company outline relief efforts.
Mylan Donates 10 Million Tablets of Potential COVID-19 Drug to US Gov’tMylan is donating 10 million...
A roundup of developments from India (Pfizer), Malaysia (Biocon), and the UK (AstraZeneca, RedHill Biopharma).
India
FDA Issues Warning Letter to Pfizer for Facility in IndiaThe US Food and Drug Administration (FDA) has issued a Warning Letter to...
Takeda and Evotec GT, an Austria-based subsidiary of Evotec, a Hamburg, Germany-based drug- discovery and development company, have entered into a long-term research alliance to support Takeda’s research-stage gene-therapy discovery...
Gilead Sciences has completed its previously announced $4.9-billion acquisition of Forty Seven Inc., a Menlo Park, California-based clinical-stage immuno-oncology company. Gilead had announced the acquisition last month (March 2020).
Forty Seven’s...
The European Medicines Agency (EMA) is setting up a single-point-of-contact system with pharmaceutical companies for reporting drug shortage or potential drug shortages related to the novel coronavirus (COVID-19) outbreak.
The EMA reports...
Gilead Sciences and Second Genome, a microbiome clinical-stage company, have entered into a four-year collaboration worth up to $338 million ($38 million upfront and up to $300 million in milestones) to identify biomarkers associated with clinical...
The European Commission (EC) has outlined three measures it is taking to advise companies on how they may cooperate with each other in addressing potential drug shortages relating to the novel coronavirus (COVID-19) while maintaining compliance...
Danaher, a global science and technology company, headquartered in Washington D.C., has completed its $21.4-billion acquisition of the biopharma business from General Electric’s Life Sciences division. As part of Danaher, the business will be...
Sanofi forms COVID-19 vaccine research pact and advances clinical testing of antiviral. Bayer and AbbVie contribute to COVID-19 relief efforts. Gates Foundation contributes $1.73 million for antibody research.
Sanofi Advances Testing of...
Eli Lilly and Company and Sitryx, an Oxford, UK-based biopharmaceutical company focused on developing therapeutics in immuno-oncology and immuno-inflammation, have entered a licensing pact in a deal worth up to $880 million ($50 million...
Takeda has formed a licensing pact with Evox Therapeutics, an Oxford, UK-headquartered biopharmaceutical company, in a deal worth up to $882 million ($44 million upfront) for the development of protein-replacement and mRNA therapies.
The...
